Is Compass Therapeutics, Inc. (CMPX) a Buy, Sell, or Hold?
Compass Therapeutics, Inc.
NASDAQ:CMPX
$2.19 USD
-$0.07 (-3.1%)
- Volume
- 2.01M
- Average Volume
- 8.15M
- Market Capitalization
- $302.85M
- P/E Ratio
- -5.15
- Dividend Yield
- 0.00%
- Price Target
- $11.00
- Year High
- $6.88
- Year Low
- $1.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $19.04
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Thomas J. Schuetz |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CMPX |
| CUSIP | 20454B104 |
| CIK | 0001738021 |
| Web | https://www.compasstherapeutics.com |
| Phone | 617 500 8099 |
| Currency | USD |
| Employees | 39 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.05 |
| Payout Ratio | 0.00 |
| Current Ratio | 19.04 |
| Quick Ratio | 19.04 |
| Cash Ratio | 5.37 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.29 |
| Price / Cash Flow | -5.68 |
| Price / Book | 2.19 |
Price Target and Rating
| Average Stock Price Forecast | $11.00 |
| High Stock Price Forecast | $15.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -80.09% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.42 |
| Trailing P/E Ratio | -5.15 |
| PEG Ratio | 0.57 |
| P/E Growth | 0.57 |
| Net Income | $-66.49M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -39.75% |
| Return on Assets | -33.23% |
Financials Score
| AltmanZ Score | 7.26 |
| Piotroski Score | 2.00 |
| Working Capital | 185.41M |
| Total Assets | 205.17M |
| Ebit | -68.17M |
| Market Cap | 322.21M |
| Total Liabilities | 18.7M |
Poll Results
About Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L ... 1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
2026-06-09 11:12:10
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
2026-06-08 09:07:00
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secondary endpoint.
Compass Therapeutics to Participate in Upcoming June Investor Events
2026-05-28 07:30:00
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.
2026-05-21 17:00:00
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced a poster presentation of data from the Phase 1 study of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies treated in the post-checkpoint inhibitor setting will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.
2026-05-21 16:00:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
2026-05-21 15:45:00
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-05-19 18:09:00
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-05-15 00:00:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
Frequently Asked Questions
-
What is the current Compass Therapeutics, Inc. (CMPX) stock price?
-
Compass Therapeutics, Inc.(NASDAQ:CMPX) stock price is $2.19 in the last trading session. During the trading session, CMPX stock reached the peak price of $6.88 while $1.61 was the lowest point it dropped to. The percentage change in CMPX stock occurred in the recent session was --3.1% while the dollar amount for the price change in CMPX stock was -$-0.07.
-
CMPX's industry and sector of operation?
-
The NASDAQ listed CMPX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CMPX?
-
Arjun Prasad | Chief Commercial Officer
Jonathan Anderman | Senior Vice President, General Counsel & Corporate Secretary
Cynthia A. Sirard | Chief Medical Officer
Thomas J. Schuetz | Chief Executive Officer & Vice Chairman
Barry Shin | Chief Financial Officer -
How many employees does CMPX have?
-
Number of CMPX employees currently stands at 39. CMPX operates from 80 Guest Street, Boston, MA 02135, US.
-
Link for CMPX official website?
-
Official Website of CMPX is: https://www.compasstherapeutics.com
-
How do I contact CMPX?
-
CMPX could be contacted at phone #617 500 8099 and can also be accessed through its website. CMPX operates from 80 Guest Street, Boston, MA 02135, US.
-
How many shares of CMPX are traded daily?
-
The average number of CMPX shares traded daily for last 3 months was 8.15M.
-
What is the market cap of CMPX currently?
-
The market value of CMPX currently stands at $302.85M with its latest stock price at $2.19